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Signaling pathways transduce extracellular stimuli into cells through molecular cascades to regulate cellular functions. In stem 
cells, a small number of pathways, notably those of TGF-/BMP, Hedgehog, Notch, and Wnt, are responsible for the regula-
tion of pluripotency and differentiation. During embryonic development, these pathways govern cell fate specifications as well 
as the formation of tissues and organs. In adulthood, their normal functions are important for tissue homeostasis and regenera-
tion, whereas aberrations result in diseases, such as cancer and degenerative disorders. In complex biological systems, stem 
cell signaling pathways work in concert as a network and exhibit crosstalk, such as the negative crosstalk between Wnt and 
Notch. Over the past decade, genetic and genomic studies have identified a number of potential drug targets that are involved 
in stem cell signaling pathways. Indeed, discovery of new targets and drugs for these pathways has become one of the most ac-
tive areas in both the research community and pharmaceutical industry. Remarkable progress has been made and several 
promising drug candidates have entered into clinical trials. This review focuses on recent advances in the discovery of novel 
drugs which target the Notch and Wnt pathways. 
stem cell, drug discovery, signaling pathways, Notch, Wnt, cancer 
 
Citation:  An SM, Ding Q, Zhang J, Xie JY, Li LS. Targeting stem cell signaling pathways for drug discovery: advances in the Notch and Wnt pathways. Sci 




Stem cell research has been one of the most exciting fields 
in biomedicine over the past few years. It has profoundly 
improved our understanding of fundamental biological pro-
cesses. The application of stem cells is a promising thera-
peutic modality, yet, cell therapy has a number of technical 
challenges and regulatory hurdles to overcome. In contrast, 
application of the principles of stem cell biology and the use 
of stem cells themselves as tools in the discovery of novel 
drugs may generate immediate returns because this ap-
proach is mature in terms of technologies and known regu-
latory pathways. In particular, the targeting of stem cell 
signaling pathways is proving to be a productive avenue for 
drug research. 
Over the past 30 years, developmental biology studies 
have revealed a small number of signal transduction path-
ways involved in stem cell self-renewal and differentiation 
that govern embryonic development. Among them, signal-
ing cascades elicited by TGF-/BMP, Hedgehog, Notch and 
Wnt proteins are particularly important. Through intracellu-
lar signaling pathways, these secreted proteins control the 
behavior of recipient stem cells or their differentiated prog-
eny. As a result, the stem cells or differentiated cells un-
dergo phenotypic changes in self-renewal, differentiation, 
proliferation, or migration. The concerted actions of these 
signals lead to specific cell fates and the formation of tis-
sues and organs. In adult tissues and organs, the activities of 
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these signaling pathways are required to maintain homeo-
stasis of the organism, as well as repair of injuries and re-
generation. 
From decades of genetic research, the key components of 
the signaling pathways and the mechanisms by which these 
signals act in embryonic development have been 
well-established. By contrast, our understanding of how 
these signals maintain tissue homeostasis and how their 
aberrations cause human diseases is still limited. The recent 
advances in stem cell research, chemical biology, and ge-
nomics have now provided the necessary tools to investigate 
these pathways in a broad range of biological systems and 
disease models. In particular, there are now unique experi-
mental opportunities to use chemical modulators of these 
pathways to explore disease mechanisms and assess their 
therapeutic value.   
1  The Notch pathway 
Among the key signaling pathways that control stem cells in 
embryonic and adult organisms, the evolutionarily con-
served Notch signaling pathway is particularly important for 
the development and maintenance of the nervous system, 
muscle, intestine and hematopoiesis. The Notch pathway 
consists of five known ligands (Jagged-1, -2, Delta-like-1, 
-3, -4) and four receptors (Notch-1, -2, -3, -4). In the ca-
nonical Notch pathway (Figure 1), ligand binding with re-
ceptor results in its proteolytic cleavages mediated first by 
ADAM metalloproteases and then by a -secretase complex. 
These cleavages of Notch result in the release of a constitu-
tively active Notch intra-cellular domain (NICD) that then 
translocates to the nucleus where it associates with a larger 
transcription complex. In net effect, NICD switches the 
transcriptional complex from a repressed to activated   
state [1,2]. 
2  The Wnt pathway 
The WNT genes were first discovered in Drosophila as 
wingless [3] and later in mouse tumors as the oncogene 
int-1 [4] (Figure 2). In humans, the WNT family is com-
posed of 19 lipidated and glycosylated proteins that play es-
sential roles in diverse processes such as stem cell 
self-renewal, differentiation, cell polarity, proliferation, and 
migration. Aberrations in the Wnt proteins, or of any of the 
signaling components in the Wnt pathway, result in abnor-
mal embryonic development or diseases [5]. 
Wnt signaling encompasses both the canonical (β- 
catenin-dependent) and the non-canonical (β-catenin-   
independent) pathways. The canonical WNT signaling 
pathway stabilizes β-catenin and the transcription of genes 
known to regulate a large array of cellular functions (Fig-  
ure 2). The non-canonical WNT signaling pathway does not 
 
Figure 1  A diagram of the Notch pathway. 
 
 
Figure 2  A diagram of the Wnt pathway. 
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activate β-catenin but instead transduces signals to affect 
cell polarity and migration through the planar cell polarity 
pathway and GTPases. 
3  Interaction between the Notch and Wnt 
pathways 
There is an increasing body of evidence that suggests that 
the stem cell signaling pathways work as a network and 
exhibit crosstalk (Figure 3). For instance, between WNT 
and Notch signaling, it was shown in fruit flies that the 
wingless downstream component disheveled binds to the 
cytoplasmic tail of Notch [6]. On the other hand, Notch lig-
and Jagged-1 has been shown to be a Wnt/β-catenin target 
gene in hair follicle formation of the adult epidermis [7]. 
More recently, Kwon et al. [8] showed a physical interac-
tion between β-catenin and the cytoplasmic tail of mem-
brane bound Notch in stem and progenitor cells. Thus only 
the active pool of β-catenin protein was able to bind Notch. 
This interaction resulted in degradation of β-catenin protein, 
suggesting that a negative interaction exists between the two 
pathways in these cells. The negative crosstalk between the 
Notch and Wnt pathways was further demonstrated in 
keratinocytes. In these cells, inhibition of Notch signaling, 
through Notch-1 KO, correlated with Wnt activation, 
whereas overexpression of either NICD or Jagged-1 down-
regulated the expression of Wnt genes [9,10]. These find-
ings have great implication for the therapeutic application of 
drugs targeting these two pathways, which will be discussed 
later in light of recent cancer genomic results. 
 
 
Figure 3  A diagram of the interaction between the Notch and Wnt path-
ways. 
4  Aberrant Notch and Wnt signaling in cancer 
Given the importance of stem cell signaling pathways in 
embryonic development, it is not surprising that genetic 
mutations that perturb their activities result in growth ab-
normalities in humans. Indeed, many physiological homeo-
static activities and pathological responses in adults are re-
lated to stem cell functions, thus aberrations in the pathways 
that regulate stem cells can result in diseases. Among the 
human diseases most affected by deregulated stem cell sig-
naling are those associated with tissue damage and repair, 
such as cancer, fibrosis, degenerative diseases and skeletal 
repair. 
5  The Notch pathway in cancer 
Notch-1 was first identified from a translocation in a subset 
of T-cell acute leukemia (T-ALL), which fuses the Notch-1 
gene to the T-cell receptor-β locus, resulting in a fusion 
protein that is constitutively active [11]. The resultant con-
stitutive Notch-1 signaling is the causative driver of this 
rare form of T-ALL. More recent work showed that greater 
than 50% of all T-ALL patients bear activating point muta-
tions in Notch-1 [12]. 
On the other hand, Notch-1 can also function as a tumor 
suppressor. In chronic myelomonocytic leukemia (CMML), 
inactivating mutations of Notch-1 have been identified, in-
dicating a tumor-suppressive role for Notch signaling [13]. 
In solid tumors, the role of Notch-1 is not as well character-
ized, however, evidence for a dual oncogene/tumor sup-
pressor role has emerged [14]. Oncogenic Notch has been 
reported in breast epithelial tumors and is believed to have a 
role in anti-estrogen resistance [15]. On the contrary, high 
frequency of loss-of-function (LoF) mutations in Notch-1 
have been discovered by several genome sequencing pro-
jects of squamous type carcinomas from the skin, head/neck, 
and lung [16]. These results suggest that the role of Notch 
signaling in cancer biology is cell and tissue context-    
dependent. 
6  The Wnt pathway in cancer 
A possible role for the Wnt pathway in cancer was first 
discovered in the 1980s in mouse models of breast cancer. 
Overexpression of Wnt1, induced by a viral insertion at the 
Wnt1 locus, was shown to cause spontaneous mammary 
hyperplasia and tumors in mice [17]. Further studies found 
that Wnt1, as well as that of other Wnts, promoted the stabi-
lization of free pools of β-catenin (CTNNB1) and the acti-
vation of CTNNB1-dependent transcription [18]. Moreover, 
inherited inactivating mutations in adenomatous polyposis 
coli (APC), part of the destruction complex which nega-
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tively regulates the WNT pathway, are found in patients 
with familial adenomatous polyposis, which can progress to 
colorectal carcinomas. In line with these data, in 1997, 
seminal studies demonstrated a crucial role for hyperac-
tivated WNT-CTNNB1 signaling in human colorectal can-
cers with frequent APC and CTNNB1 mutations [19,20]. 
Strikingly, activating CTNNB1 mutations or inactivating 
APC mutations occur in more than 80% of patients with 
colorectal cancer. Moreover, an additional 10% of colorec-
tal tumors harbor fusion mutations of two other Wnt path-
way genes encoding R-spondin-2 and R-spondin-3, enhanc-
ers of the Wnt pathway [21]. These observations establish 
that the unregulated activation of the Wnt pathway is the 
most important oncogenic event in colorectal tumorigenesis.  
In addition to colorectal cancer, several other types of 
cancer also carry mutations in the WNT pathway. For ex-
ample, liver cancer has an approximately 25% chance of 
gaining activating mutations in CTNNB1 or APC, while 
gastric cancer has an approximately 20% chance (Sanger 
Cancer Genome Project database, http://cancer.sanger.ac. 
uk/cancergenome/projects/cosmic/). Of note, liver cancer 
and gastric cancer, along with colorectal cancer, are some of 
the most prevalent types of cancer in China and other parts 
of the world. 
 
7  Drug discovery for the notch and Wnt path-
ways 
Drug discovery based on the Wnt and Hedgehog pathways 
has been one of the most active areas in the drug discovery 
field over the past decade. Many pharmaceutical companies 
and research institutes have been actively searching for both 
small molecule and large molecule drugs that target these 
pathways. Recently, remarkable progress has been made in 
the search for new drugs. 
8  Targeting the Notch pathway for cancer 
Given the importance of the Notch pathway in many types 
of cancer, it is not surprising that the discovery of drugs that 
target this pathway is currently actively pursued by both the 
pharmaceutical and biotech industries. Several feasible tar-
gets have been the focus of these efforts. As shown in Table 
1, the first group of compounds is inhibitors of the 
-secretase complex that process Notch to generate NCID. 
Several antibodies against either the ligand DLL-4 or the 
receptors Notch-1, -2 or -3 are also in clinical development 
for the treatment of T-ALL and certain solid tumors. Nota-
bly, all of these compounds are inhibitors of the Notch 
pathway, which would be useful for certain cancers with 
activating, but not inactivating, mutations. 
Table 1  Notch pathway inhibitors in clinical trials for cancer 
Compound name Target Company 
BMS-906024 γ-secretase  BMS 
MK0752 γ-secretase  Merck 
PF-03084014  γ-secretase  Pfizer 
RO4929097  γ-secretase  Roche 
Enoticumab (REGN421)  DLL-4 Regeneron 
MEDI0639  DLL-4 MedImmune 
Demcizumab (OMP-21M18) DLL-4 OncoMed 
OMP-59R5  Notch-2/3 OncoMed 
OMP-52M51  Notch-1 OncoMed 
9  Targeting the Wnt pathway for cancer 
Given the prevalence of mutations in APC and β-catenin in 
many types of cancer, the drug industry has been searching 
for the elusive inhibitor that blocks β-catenin transactivation. 
However, because of a lack of an appropriate target down-
stream of APC or β-catenin, this approach has failed. Cur-
rently, the industry focus is on the identification of appro-
priate upstream targets. To this end, several promising pro-
grams have entered clinical trials over the past two to three 
years (Table 2). 
One of the most advanced clinical programs is an an-
ti-Frizzled antibody from OncoMed Pharmaceuticals that 
entered into Phase I clinical trials in 2011. Published data 
show that this pan-Frizzled antibody (OMP18R5) has re-
markable anti-tumor efficacy in many preclinical pa-
tient-derived xenograft models [22]. Similar to OMP18R5, 
OncoMed has several other WNT pathway inhibitors in 
their pipeline, including a Frizzled-8 Fc fusion protein and 
an antibody against R-spondin/LGR5 interaction. 
Also in Phase I clinical trials is a small molecule inhibi-
tor of Porcupine, an acetyl-transferase responsible for the 
lipidation, and hence the bioactivity, of all WNT proteins. 
The molecule, LGK974, is developed by Novartis and cur-
rently being tested against multiple types of cancer 
(http://clinicaltrials.gov/show/NCT01351103). 
Several WNT inhibitors have also been pursued in pre-
clinical studies. For example, by screening for agents that 
specifically kill cancer stem cells, Weinberg, Lander, and 
colleagues discovered compounds that are selectively toxic 
to cancer stem cells isolated from breast cancers. One com-
pound, salinomycin, inhibited mammary tumor growth in 
vivo and induced increased epithelial differentiation of tu-
mor stem cells [23]. A subsequent study by another group 
demonstrated that salinomycin is a potent inhibitor of the 
Wnt signaling cascade and acts by interfering with the 
phosphorylation of LPR6 which is a Wnt receptor [24]. The 
compound was once pursued by the biotech company 
Verastem in a preclinical study for the development of a 
drug targeting breast cancer. 
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Table 2  Wnt pathway inhibitors in clinical trials for cancer 
Compound name Target Company 
LGK974  Porcupine  Novartis 
Vantictumab (OMP-18R5) Fzd7/pan Fzds OncoMed 
OMP-54F28  Fzd8 (Fzd8-Fc fusion) OncoMed 
OTSA101  Fzd10  Centre Leon Berard 
10  Targeting the crosstalk between the Notch 
and Wnt pathways 
As described previously, Notch-1 can be a tumor suppressor 
in certain types of cancers, such as CMML and squamous 
type carcinomas from the skin, head-neck, and lung. 
Large-scale cancer genome projects have revealed 
loss-of-function mutations of Notch-1 in a large number of 
squamous carcinomas from the head-neck region and upper 
aerodigestive tract, including the oral cavity, oropharynx, 
larynx, thyroid, neck, esophagus, and lung (data available at 
the Sanger database http://cancer.sanger.ac.uk/cosmic/gene/ 
overview?ln=NOTCH1; ICGC http://dcc.icgc.org/genes/ 
ENSG00000148400; and TCGA https://tcga-data.nci.nih. 
gov/tcga/). Notably, cancers that originate from these ana-
tomic sites, such as nasopharyngeal cancer and esophageal 
cancer, are particularly prevalent in areas of China. 
Logically, tumor suppressors are difficult or impossible 
to target by conventional therapeutic modalities because the 
loss of a gene cannot be easily replaced in patients. Thus, 
the LoF mutation of Notch-1 would be impossible to target 
directly by using small molecule compounds or antibodies. 
Fortunately, it is still theoretically possible to indirectly 
target pathways where tumor suppressors are involved. 
Such approaches include (i) targeting the downstream 
components of the pathway; (ii) targeting by synthetic le-
thality, for example, through inhibiting another pathway 
that interacts with the tumor suppressor. Given the afore-
mentioned notion that the Notch pathway might negatively 
control the Wnt pathway, i.e., LoF of Notch-1 indirectly 
activates the Wnt pathway; a plausible approach to target 
Notch-1 negative tumors would be to inhibit Wnt signaling. 
A recent publication by Liu et al. [25] suggested that this 
just may be correct. In this study, Liu and co-workers from 
Novartis screened hundreds of cancer cell lines for their 
sensitivity to the Wnt pathway inhibitor LGK974. They 
found that a number of head-neck cancer cell lines were 
sensitive to LGK974. Interestingly, all of the sensitive cell 
lines harbored Notch-1 mutations that were predicted to be 
LoF mutations. In xenograft models of HN30 and FaDu 
(both derived from nasopharyngeal tumors), LGK974 dra-
matically inhibited the growth of the tumors at doses 
well-tolerated in mice. This study is consistent with previ-
ous observations in terms of the interaction between the two 
pathways and strongly supports clinical testing of Wnt 
pathway inhibitors in a large number of cancer patients with 
Notch-1 LoF mutations. 
11  Conclusion 
Stem cell research offers great promise not only for cell 
replacement therapy but also for drug discovery. Over the 
past few years, remarkable progress has been made in the 
search for drugs that target two of the most important stem 
cell pathways, Notch and Wnt. By applying advances in 
stem cell signaling biology and cancer genomics, drug dis-
covery in this field has become very active. Of particular 
interest to the Chinese pharmaceutical and research com-
munities is the frequency of Notch mutations in cancer 
types prevalent in China and the therapeutic potential of 
WNT inhibitors for their treatment. The continued ad-
vancement of this area of research and drug discovery may 
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